Talsupram

Talsupram

Talsupram

Chemical compound

Talsupram (Lu 5-005 or Lu 5-003[1]) is a selective norepinephrine reuptake inhibitor (NRI) which was investigated as an antidepressant in the 1960s and 1970s but was never marketed.[2][3][4] Along with talopram, it is structurally related to the selective serotonin reuptake inhibitor (SSRI) citalopram.[5]

Quick Facts Clinical data, Routes ofadministration ...

See also

References

  1. [1]
    Carlsson A, Fuxe K, Hamberger B, Malmfors T (May 1969). "Effect of a new series of bicyclic compounds with potential thymoleptic properties on the reserpine-resistant uptake mechanism of central and peripheral monoamine neurones in vivo and in vitro". British Journal of Pharmacology. 36 (1): 18–28. doi:10.1111/j.1476-5381.1969.tb08299.x. ISSN 0007-1188. OCLC 6895508396. PMC 1703539. PMID 5768100.
  2. [2]
    Pawłowski L, Mazela H (June 1986). "Effects of antidepressant drugs, selective noradrenaline-or 5-hydroxytryptamine uptake inhibitors, on apomorphine-induced hypothermia in mice". Psychopharmacology. 88 (2): 240–246. doi:10.1007/BF00652248. ISSN 0033-3158. OCLC 5653283278. PMID 3006113. S2CID 1732297.
  3. [3]
    McConathy J, Owens MJ, Kilts CD, et al. (August 2004). "Synthesis and biological evaluation of [11C]talopram and [11C]talsupram: candidate PET ligands for the norepinephrine transporter". Nuclear Medicine and Biology. 31 (6): 705–18. doi:10.1016/j.nucmedbio.2003.05.001. PMID 15246361.
  4. [4]
    Kelliher P, Kelly JP, Leonard BE, Sánchez C (April 2003). "Effects of acute and chronic administration of selective monoamine re-uptake inhibitors in the rat forced swim test". Psychoneuroendocrinology. 28 (3): 332–47. doi:10.1016/S0306-4530(02)00026-4. PMID 12573300. S2CID 23452713.
  5. [5]
    "The SSRI Issues" (DOC). healyprozac.com. Retrieved January 3, 2024.


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Talsupram, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.